Drug intelligence / Profile preview

docetaxel + imatinib

Development stage: Unknown
Lead developer: Novartis
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

A combination therapy consisting of docetaxel, a taxane chemotherapy agent, and imatinib mesylate, a tyrosine kinase inhibitor. This combination has been studied for its potential synergistic effects in various cancer types, particularly in recurrent or resistant solid tumors. Imatinib appears to enhance docetaxel's effectiveness by blocking antiapoptotic signaling pathways induced by docetaxel treatment and potentially improving drug delivery to tumors.

Brand names: TaxotereGleevec
Other names: docetaxel and imatinib mesylateimatinib mesylate and docetaxel

Targets

ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFR (PDGFR family)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on docetaxel + imatinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on docetaxel + imatinib.

Explore the full profile